AI Engines For more Details: Perplexity Kagi Labs You
Acute Diarrhea: Racecadotril is highly effective in reducing the duration and severity of acute diarrhea episodes in both adults and children. It helps alleviate symptoms such as frequent bowel movements, watery stools, abdominal cramps, and dehydration.
Viral Gastroenteritis: Racecadotril can be used to manage acute diarrhea caused by viral gastroenteritis, which is a common condition characterized by inflammation of the stomach and intestines due to viral infection.
Bacterial Gastroenteritis: In cases of acute diarrhea caused by bacterial infections such as Escherichia coli or Salmonella, racecadotril may be used as an adjunctive therapy to antibiotics to help control diarrhea symptoms.
Traveler's Diarrhea: Racecadotril may be beneficial for individuals experiencing traveler's diarrhea, which often occurs when traveling to regions with poor sanitation or consuming contaminated food or water.
Chemotherapy-Induced Diarrhea: Some chemotherapy medications can cause diarrhea as a side effect. Racecadotril may be used to manage chemotherapy-induced diarrhea, helping to reduce the frequency and severity of diarrhea episodes in cancer patients undergoing treatment.
Postoperative Diarrhea: After certain surgeries, particularly those involving the gastrointestinal tract, patients may experience diarrhea as a complication. Racecadotril may be prescribed to manage postoperative diarrhea and promote faster recovery.
Functional Diarrhea: Racecadotril may also be used in the management of functional diarrhea, which is diarrhea that occurs without an identifiable underlying cause. It can help improve stool consistency and reduce bowel movement frequency in individuals with this condition.
Dehydration Prevention: By reducing the severity and duration of diarrhea episodes, racecadotril can help prevent dehydration, a common complication of acute diarrhea, especially in children and older adults.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 3 | 0.6 | 4 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.8 | 1.25 |
| Allergies | 2.9 | 2.1 | 0.38 |
| Allergy to milk products | 1.2 | 1 | 0.2 |
| Alopecia (Hair Loss) | 0.8 | 0.8 | |
| Alzheimer's disease | 4.2 | 2.3 | 0.83 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.4 | 1.75 |
| Ankylosing spondylitis | 2 | 1.2 | 0.67 |
| Anorexia Nervosa | 1.5 | 1.7 | -0.13 |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 2.5 | 1.4 | 0.79 |
| Atherosclerosis | 1.8 | 0.5 | 2.6 |
| Atrial fibrillation | 2.2 | 1 | 1.2 |
| Autism | 4.5 | 4 | 0.13 |
| Autoimmune Disease | 0.6 | 0.5 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.5 | 0.9 | 0.67 |
| Brain Trauma | 0.9 | 0.9 | 0 |
| Breast Cancer | 0.5 | 0.3 | 0.67 |
| Cancer (General) | 0.9 | 0.2 | 3.5 |
| Carcinoma | 3 | 1.9 | 0.58 |
| Celiac Disease | 1.6 | 1.9 | -0.19 |
| Cerebral Palsy | 1.4 | 0.6 | 1.33 |
| Chronic Fatigue Syndrome | 3.6 | 2.4 | 0.5 |
| Chronic Kidney Disease | 2 | 0.4 | 4 |
| Chronic Lyme | 0.1 | 0.3 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 0.9 | 0 |
| Chronic Urticaria (Hives) | 0.8 | 0.5 | 0.6 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.6 | 0.17 |
| Cognitive Function | 1.9 | 1.1 | 0.73 |
| Colorectal Cancer | 4.9 | 1.4 | 2.5 |
| Constipation | 0.7 | 0 | 0 |
| Coronary artery disease | 1.2 | 1.2 | 0 |
| COVID-19 | 5.2 | 4.2 | 0.24 |
| Crohn's Disease | 5.5 | 2.7 | 1.04 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.7 | -0.7 | |
| deep vein thrombosis | 1 | 0.9 | 0.11 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 5.6 | 3.4 | 0.65 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 1.2 | 0.17 |
| Endometriosis | 1.3 | 0.9 | 0.44 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 1.9 | 1.4 | 0.36 |
| erectile dysfunction | 1.5 | 0.3 | 4 |
| Fibromyalgia | 1.8 | 1.4 | 0.29 |
| Functional constipation / chronic idiopathic constipation | 2.7 | 1.9 | 0.42 |
| gallstone disease (gsd) | 1.9 | 0.6 | 2.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.3 | 3.33 |
| Generalized anxiety disorder | 1.5 | 1.1 | 0.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.6 | 0.5 |
| Graves' disease | 1.9 | 1.7 | 0.12 |
| Gulf War Syndrome | 0.5 | 1.1 | -1.2 |
| Halitosis | 1.4 | 0.3 | 3.67 |
| Hashimoto's thyroiditis | 1.9 | 0.6 | 2.17 |
| Heart Failure | 2.2 | 0.7 | 2.14 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.3 | 0.6 | -1 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.1 | 4 |
| hyperglycemia | 0.7 | 1.2 | -0.71 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.3 | 2.3 | 0 |
| Hypothyroidism | 0.1 | 0.6 | -5 |
| Hypoxia | 1.3 | 0.3 | 3.33 |
| IgA nephropathy (IgAN) | 1.9 | 2.2 | -0.16 |
| Inflammatory Bowel Disease | 5 | 3.6 | 0.39 |
| Insomnia | 0.9 | 1.4 | -0.56 |
| Intelligence | 1.1 | 1.1 | |
| Intracranial aneurysms | 1.3 | 0.6 | 1.17 |
| Irritable Bowel Syndrome | 3.2 | 3.4 | -0.06 |
| ischemic stroke | 1.9 | 0.3 | 5.33 |
| Liver Cirrhosis | 3.5 | 2.7 | 0.3 |
| Long COVID | 4 | 2.8 | 0.43 |
| Lung Cancer | 0.4 | -0.4 | |
| Mast Cell Issues / mastitis | 0.5 | 0.6 | -0.2 |
| ME/CFS with IBS | 0.5 | 0.6 | -0.2 |
| ME/CFS without IBS | 1.3 | 1.1 | 0.18 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.5 | 0.1 | 4 |
| Metabolic Syndrome | 3.7 | 4 | -0.08 |
| Mood Disorders | 5.7 | 3.1 | 0.84 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.7 | |
| Multiple Sclerosis | 2.7 | 2.8 | -0.04 |
| Multiple system atrophy (MSA) | 0.2 | 0.6 | -2 |
| myasthenia gravis | 0.3 | 0.2 | 0.5 |
| neuropathic pain | 0.3 | 0.9 | -2 |
| Neuropathy (all types) | 0.6 | 0.6 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 1.5 | 0.67 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 4.5 | 4.8 | -0.07 |
| obsessive-compulsive disorder | 2.7 | 1.6 | 0.69 |
| Osteoarthritis | 2.2 | 1.2 | 0.83 |
| Osteoporosis | 1.4 | 0.7 | 1 |
| pancreatic cancer | 0.8 | 0.3 | 1.67 |
| Parkinson's Disease | 3.8 | 3.3 | 0.15 |
| Polycystic ovary syndrome | 3.7 | 1.8 | 1.06 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.6 | 1.7 | -1.83 |
| Primary sclerosing cholangitis | 1.9 | 1.8 | 0.06 |
| Psoriasis | 1.8 | 1.4 | 0.29 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 2.3 | 0.26 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 4.2 | 1.9 | 1.21 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 1.4 | 1.7 | -0.21 |
| Sleep Apnea | 0.9 | 0.9 | 0 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 1.4 | |
| Stress / posttraumatic stress disorder | 1.6 | 1.6 | 0 |
| Systemic Lupus Erythematosus | 3 | 1.4 | 1.14 |
| Tic Disorder | 1 | 0.6 | 0.67 |
| Tourette syndrome | 0.4 | 0.3 | 0.33 |
| Type 1 Diabetes | 2.1 | 1.6 | 0.31 |
| Type 2 Diabetes | 3.9 | 4.1 | -0.05 |
| Ulcerative colitis | 3.1 | 3.6 | -0.16 |
| Unhealthy Ageing | 2.6 | 1.1 | 1.36 |
| Vitiligo | 2 | 1 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
